George A. Samuel III - Feb 11, 2025 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role
General Counsel
Signature
/s/ George A. Samuel III
Stock symbol
LCTX
Transactions as of
Feb 11, 2025
Transactions value $
-$1,586
Form type
4
Date filed
2/12/2025, 04:30 PM
Previous filing
Nov 26, 2024
Next filing
Mar 12, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LCTX Common Shares Options Exercise +6.08K +27.39% 28.3K Feb 11, 2025 Direct F1, F2
transaction LCTX Common Shares Tax liability -$1.59K -2.44K -8.63% $0.65 25.8K Feb 11, 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LCTX Restricted Stock Units Options Exercise $0 -6.08K -50% $0.00 6.08K Feb 11, 2025 Common Shares 6.08K $0.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis.
F2 Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options.
F3 Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 6,076 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction
F4 The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026.